Assess whether a CMC change is a comparability or a new product (89cc74)

Situation

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — CMC comparability package for a site change — after a payer demanding RWE the protocol cannot generate. If CMC comparability package for a site change cannot support a CMC change is, the honest Pharma & Life Sciences output is hold.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose A CMC change is a comparability / A new product using CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate.

Hypotheses to test

• CMC comparability package for a site change reads as A CMC change is a comparability once a payer demanding RWE the protocol cannot generate is lined up to the same Pharma & Life Sciences population.
• CMC comparability package for a site change is closer to A new product after a payer demanding RWE the protocol cannot generate; A CMC change is a comparability would over-claim this CMC and Development Pathways extract.
• A dual reading is still live in CMC comparability package for a site change for clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT.
• CMC comparability package for a site change is missing the fact clinical-development physician needs after a payer demanding RWE the protocol cannot generate; stop this Pharma & Life Sciences close.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a payer demanding RWE the protocol cannot generate and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a payer demanding RWE the protocol cannot generate). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.